Hyaluronic Acid Therapy in Hip OA Does Not Perform Equally in Osteoarthritis Secondary to Juvenile Idiopathic Arthritis When Compared to Primary Osteoarthritis: A 2-Year Preliminary Evaluation.
Hip osteoarthritis
Hylan G-F 20
JIA
Pain
Viscosupplementation
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
17
10
2021
accepted:
07
12
2021
pubmed:
18
1
2022
medline:
16
3
2022
entrez:
17
1
2022
Statut:
ppublish
Résumé
Hip involvement in juvenile idiopathic arthritis (JIA) is one of most important causes of pain and disability. Total hip arthroplasty (THA) is considered the standard when medical approaches fail to relieve pain. However, THA is problematic for many reasons. As current literature lacks studies valuating medical management of osteoarthritis (OA) secondary to JIA, we assessed the long-term pain relief effect of US-guided intra-articular viscosupplementation in hip osteoarthritis secondary to JIA versus primary OA under different etiological conditions. Patients in both groups received intra-articular Hylan G-F 20 2 ml once a month for 3 consecutive months and every 6 months for 2 years as maintenance. Effectiveness (VAS and WOMAC), NSAID/analgesic consumption, tolerability, withdrawals and reason for discontinuation were collected at each time point. An inverse probability weighting was used to balance the two groups. We retrospectively retrieved data of 14 JIA patients and 26 primary OA. Weighting successfully accounted for differences between the disease groups supporting the results. Viscosupplementation led to an early and significant improvement of pain and function and concomitant decrease in NSAIDs consumption, while the response diverged over 1 year with loss of benefits in JIA. The worst outcome was observed in active JIA. Duration of symptom relief after intra-articular injection of hyaluronic acid depends on the nature of arthritis. Multiple courses of viscosupplementation are required to maintain low-dose NSAIDs consumption in patients responsive to treatment while shortening the time between consecutive injections might provide persistent positive results in patients suffering from JIA.
Identifiants
pubmed: 35038122
doi: 10.1007/s12325-021-02020-1
pii: 10.1007/s12325-021-02020-1
doi:
Substances chimiques
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Langues
eng
Pagination
1267-1278Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Oen KG, Cheang M. Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum. 1996;26:575–91. https://doi.org/10.1016/s0049-0172(96)80009-6 .
doi: 10.1016/s0049-0172(96)80009-6
pubmed: 8989803
Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, Childhood Arthritis Rheumatology Research A, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63:929–36. https://doi.org/10.1002/acr.20497 .
doi: 10.1002/acr.20497
Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatol (Oxf). 2000;39:198–204. https://doi.org/10.1093/rheumatology/39.2.198 .
doi: 10.1093/rheumatology/39.2.198
Tollisen A, Selvaag AM, Aulie HA, Lilleby V, Aasland A, Lerdal A, et al. Physical functioning, pain, and health-related quality of life in adults with juvenile idiopathic arthritis: a longitudinal 30-year followup study. Arthritis Care Res (Hoboken). 2018;70:741–9. https://doi.org/10.1002/acr.23327 .
doi: 10.1002/acr.23327
Luque Ramos A, Redeker I, Hoffmann F, Callhoff J, Zink A, Albrecht K. Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes: results of claims data linked to questionnaire survey. J Rheumatol. 2019;46:564–71. https://doi.org/10.3899/jrheum.180668 .
doi: 10.3899/jrheum.180668
pubmed: 30647170
Marino A, Pontikaki I, Truzzi M, Menon A, Artusi C, Di Marco M, et al. Early joint replacement in juvenile idiopathic arthritis (JIA): trend over time and factors influencing implant survival. Arthritis Care Res (Hoboken). 2020. https://doi.org/10.1002/acr.24337 .
doi: 10.1002/acr.24337
Mertelsmann-Voss C, Lyman S, Pan TJ, Goodman SM, Figgie MP, Mandl LA. US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis. Arthritis Rheumatol. 2014;66:1432–9. https://doi.org/10.1002/art.38384 .
doi: 10.1002/art.38384
pubmed: 24591462
Malviya A, Walker LC, Avery P, Osborne S, Weir DJ, Foster HE, et al. The long-term outcome of hip replacement in adults with juvenile idiopathic arthritis: the influence of steroids and methotrexate. J Bone Joint Surg Br. 2011;93:443–8. https://doi.org/10.1302/0301-620X.93B4.26078 .
doi: 10.1302/0301-620X.93B4.26078
pubmed: 21464480
Odent T, Journeau P, Prieur AM, Touzet P, Pouliquen JC, Glorion C. Cementless hip arthroplasty in juvenile idiopathic arthritis. J Pediatr Orthop. 2005;25:465–70. https://doi.org/10.1097/01.bpo.0000161096.53963.0e .
doi: 10.1097/01.bpo.0000161096.53963.0e
pubmed: 15958896
Polkowski GG, Callaghan JJ, Mont MA, Clohisy JC. Total hip arthroplasty in the very young patient. J Am Acad Orthop Surg. 2012;20:487–97. https://doi.org/10.5435/JAAOS-20-08-487 .
doi: 10.5435/JAAOS-20-08-487
pubmed: 22855851
Swarup I, Lee YY, Christoph EI, Mandl LA, Goodman SM, Figgie MP. Implant survival and patient-reported outcomes after total hip arthroplasty in young patients with juvenile idiopathic arthritis. J Arthroplasty. 2015;30:398–402. https://doi.org/10.1016/j.arth.2014.09.018 .
doi: 10.1016/j.arth.2014.09.018
pubmed: 25449584
Li XA, Iyer S, Cross MB, Figgie MP. Total joint replacement in adolescents: literature review and case examples. Curr Opin Pediatr. 2012;24:57–63. https://doi.org/10.1097/MOP.0b013e32834ec96a .
doi: 10.1097/MOP.0b013e32834ec96a
pubmed: 22245907
Wilson MG, Michet CJ Jr, Ilstrup DM, Melton LJ 3rd. Idiopathic symptomatic osteoarthritis of the hip and knee: a population-based incidence study. Mayo Clin Proc. 1990;65:1214–21. https://doi.org/10.1016/s0025-6196(12)62745-1 .
doi: 10.1016/s0025-6196(12)62745-1
pubmed: 2402161
Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:3–9.
pubmed: 8410881
Avenoso A, D’Ascola A, Scuruchi M, Mandraffino G, Calatroni A, Saitta A, et al. Hyaluronan in experimental injured/inflamed cartilage: in vivo studies. Life Sci. 2018;193:132–40. https://doi.org/10.1016/j.lfs.2017.11.006 .
doi: 10.1016/j.lfs.2017.11.006
pubmed: 29126884
De Lucia O, Murgo A, Pregnolato F, Pontikaki I, De Souza M, Sinelli A, et al. Hyaluronic acid injections in the treatment of osteoarthritis secondary to primary inflammatory rheumatic diseases: a systematic review and qualitative synthesis. Adv Ther. 2020;37:1347–59. https://doi.org/10.1007/s12325-020-01256-7 .
doi: 10.1007/s12325-020-01256-7
pubmed: 32141016
pmcid: 7140740
Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020;72:149–62. https://doi.org/10.1002/acr.24131 .
doi: 10.1002/acr.24131
Migliore A, Martin LS, Alimonti A, Valente C, Tormenta S. Efficacy and safety of viscosupplementation by ultrasound-guided intra-articular injection in osteoarthritis of the hip. Osteoarthr Cartil. 2003;11:305–6. https://doi.org/10.1016/s1063-4584(03)00008-6 .
doi: 10.1016/s1063-4584(03)00008-6
De Lucia O, Pierannunzii LM, Pregnolato F, Verduci E, Crotti C, Valcamonica E, et al. Effectiveness and tolerability of repeated courses of viscosupplementation in symptomatic hip osteoarthritis: a retrospective observational cohort study of high molecular weight vs medium molecular weight hyaluronic acid vs no viscosupplementation. Front Pharmacol. 2019;10:1007. https://doi.org/10.3389/fphar.2019.01007 .
doi: 10.3389/fphar.2019.01007
pubmed: 31616292
pmcid: 6768944
Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505–14. https://doi.org/10.1002/art.1780340502 .
doi: 10.1002/art.1780340502
pubmed: 2025304
Kalton G, Flores-Cervantes I. Weighting methods. J Off Stat. 2003;19:81–97.
Olmos A, Govindasamy P. A Practical guide for using propensity score weighting in R. Pract Assess Res Eval. 2015;20:1–8.
Olmos A, Govindasamy P. Propensity scores: a practical introduction using R. J Multidiscipl Eval. 2015;11:68–88.
Richette P, Ravaud P, Conrozier T, Euller-Ziegler L, Mazieres B, Maugars Y, et al. Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial. Arthritis Rheum. 2009;60:824–30. https://doi.org/10.1002/art.24301 .
doi: 10.1002/art.24301
pubmed: 19248105
Jones GC, Riley GP. ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther. 2005;7:160–9. https://doi.org/10.1186/ar1783 .
doi: 10.1186/ar1783
pubmed: 15987500
pmcid: 1175049
Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet. 2000;16:83–7. https://doi.org/10.1016/s0168-9525(99)01926-5 .
doi: 10.1016/s0168-9525(99)01926-5
pubmed: 10652535
Popko J, Zalewska A, Golaszewska Z, Marciniak J, Sierakowski S, Worowski K, et al. Comparative analysis of hexosaminidase and cathepsin D expression in synovial fluid of patients with rheumatoid arthritis and traumatized joints. Clin Exp Rheumatol. 2005;23:725–6.
pubmed: 16173259
Popko J, Marciniak J, Zalewska A, Maldyk P, Rogalski M, Zwierz K. The activity of exoglycosidases in the synovial membrane and knee fluid of patients with rheumatoid arthritis and juvenile idiopathic arthritis. Scand J Rheumatol. 2006;35:189–92. https://doi.org/10.1080/03009740500474529 .
doi: 10.1080/03009740500474529
pubmed: 16766365
Shikhman AR, Brinson DC, Lotz M. Profile of glycosaminoglycan-degrading glycosidases and glycoside sulfatases secreted by human articular chondrocytes in homeostasis and inflammation. Arthritis Rheum. 2000;43:1307–14. https://doi.org/10.1002/1529-0131(200006)43:6%3c1307::AID-ANR13%3e3.0.CO;2-3 .
doi: 10.1002/1529-0131(200006)43:6<1307::AID-ANR13>3.0.CO;2-3
pubmed: 10857789
Li RW, Freeman C, Yu D, Hindmarsh EJ, Tymms KE, Parish CR, et al. Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:1590–600. https://doi.org/10.1002/art.23489 .
doi: 10.1002/art.23489
pubmed: 18512775
Winsz-Szczotka K, Mencner L, Olczyk K. Metabolism of glycosaminoglycans in the course of juvenile idiopathic arthritis. Postepy Hig Med Dosw (Online). 2016;70:135–42. https://doi.org/10.5604/17322693.1196355 .
doi: 10.5604/17322693.1196355
Winsz-Szczotka K, Komosinska-Vassev K, Kuznik-Trocha K, Gruenpeter A, Lachor-Motyka I, Olczyk K. Influence of proteolytic-antiproteolytic enzymes and prooxidative-antioxidative factors on proteoglycan alterations in children with juvenile idiopathic arthritis. Clin Biochem. 2014;47:829–34. https://doi.org/10.1016/j.clinbiochem.2014.01.027 .
doi: 10.1016/j.clinbiochem.2014.01.027
pubmed: 24495859
Winsz-Szczotka K, Kuznik-Trocha K, Komosinska-Vassev K, Wisowski G, Gruenpeter A, Lachor-Motyka I, et al. Plasma and urinary glycosaminoglycans in the course of juvenile idiopathic arthritis. Biochem Biophys Res Commun. 2015;458:639–43. https://doi.org/10.1016/j.bbrc.2015.02.018 .
doi: 10.1016/j.bbrc.2015.02.018
pubmed: 25684189
Lipinska J, Lipinska S, Stanczyk J, Sarniak A, Przyminska-vel-Prymont A, Kasielski M, et al. Reactive oxygen species and serum antioxidant defense in juvenile idiopathic arthritis. Clin Rheumatol. 2015;34:451–6. https://doi.org/10.1007/s10067-014-2571-9 .
doi: 10.1007/s10067-014-2571-9
pubmed: 24651913
Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529–43. https://doi.org/10.2741/1817 .
doi: 10.2741/1817
pubmed: 16146751
Viswanath V, Myles A, Dayal R, Aggarwal A. Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthesitis-related arthritis category of juvenile idiopathic arthritis. J Rheumatol. 2011;38:2482–7. https://doi.org/10.3899/jrheum.110352 .
doi: 10.3899/jrheum.110352
pubmed: 21885500
Peake NJ, Khawaja K, Myers A, Jones D, Cawston TE, Rowan AD, et al. Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study. Rheumatol (Oxf). 2005;44:1383–9. https://doi.org/10.1093/rheumatology/kei025 .
doi: 10.1093/rheumatology/kei025
Hoeber S, Aly AR, Ashworth N, Rajasekaran S. Ultrasound-guided hip joint injections are more accurate than landmark-guided injections: a systematic review and meta-analysis. Br J Sports Med. 2016;50:392–6. https://doi.org/10.1136/bjsports-2014-094570 .
doi: 10.1136/bjsports-2014-094570
pubmed: 26062955